MARKET

CLRB

CLRB

Cellectar
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.400
0.000
0.00%
After Hours: 1.400 0 0.00% 19:31 08/07 EDT
OPEN
1.400
PREV CLOSE
1.400
HIGH
1.420
LOW
1.380
VOLUME
423.37K
TURNOVER
--
52 WEEK HIGH
3.330
52 WEEK LOW
1.011
MARKET CAP
33.60M
P/E (TTM)
-0.8462
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CLRB stock price target is 5.57 with a high estimate of 10.00 and a low estimate of 3.000.

EPS

CLRB News

More
Cellectar Announces Poster Presentation at the International Symposium on Pediatric Neuro-Oncology (ISPNO) Annual Meeting
Data highlight results from the Phase 1 study of CLR 131 in children and adolescents with relapsed/refractory malignanciesFLORHAM PARK, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical compa
GlobeNewswire · 4d ago
TAOP, KODK among premarket losers
Seeking Alpha · 07/31 12:16
Healthcare - Top 5 Gainers / Losers
Seeking Alpha · 07/30 15:04
QCOM, UPS among premarket gainers
Seeking Alpha · 07/30 12:24
2 “Strong Buy” Healthcare Stocks That Could Be the Next M&A Target
Which stocks have been the stars of 2020? Biotechs. Amid the onset of the global health crisis, companies advancing COVID-19 vaccines, treatments and testing kits have seen their shares take off rapidly on an upward trajectory. That said, Wall Street focus has
TipRanks · 07/29 19:31
Cellectar Biosciences Granted European Patent Number EP3229810 Titled 'PHOSPHOLIPID ETHER ANALOGS AS CANCER-TARGETING DRUG VEHICLES
https://data.epo.org/publication-server/pdf-document?pn=3229810&ki=B1&cc=EP
Benzinga · 07/22 14:14
Cellectar Announces Poster Presentation of Clinical Data at the American Association of Cancer Research (AACR) Annual Meeting
FLORHAM PARK, N.J., July 21, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.
GlobeNewswire · 07/21 12:00
62 Stocks Moving In Monday's Mid-Day Session
Gainers Ayro, Inc. (NASDAQ: AYRO) shares jumped 105.8% to $6.73 after the company completed its factory expansion that will allow it to handle up to 600 EVs per month, compared to only 200 per month before the expansion.
Benzinga · 07/06 16:26

Industry

Pharmaceuticals
+0.19%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About CLRB

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. The Company’s research and development program is based on its PDC cancer-targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. Its PDC therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. The Company’s product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900). The CLR 1900 Series is targeted for solid tumors with a payload that inhibits mitosis a validated pathway for treating cancers.
More

Webull offers kinds of Cellectar Biosciences Inc stock information, including NASDAQ:CLRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLRB stock methods without spending real money on the virtual paper trading platform.